September 12, 2015 Millie D. Long MD, MPH, FACG

Size: px
Start display at page:

Download "September 12, 2015 Millie D. Long MD, MPH, FACG"

Transcription

1 Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn s disease induction and maintenance Role of combined therapy with anti-tnf (Aza/6MP vs. MTX) Comparative effectiveness with different anti-tnf Recapturing response with a second anti-tnf Anti-integrin therapy efficacy and timing Ulcerative colitis induction and maintenance Role of combined therapy with anti-tnf (Aza/6MP) Anti-integrin therapy efficacy and timing Specific role of escalated anti-tnf dosing in severe UC 1

2 Anti-TNF Therapy + 6MP/Aza or MTX in Crohn s Disease SONIC: Corticosteroid-Free Clinical Remission at Week 26 and 50 p<0.001 p<0.02 p<0.001 p<0.006 p<0.04 p<0.03 *250/508 (55%) entered study extension at week 26, results assume patients not entering extension trial were not in remission in week 26 Colombel et al N Engl J Med Apr 15;362(15):

3 SONIC: Trough Levels at Week 46 on Mono versus Combination Therapy Colombel et al N Engl J Med Apr 15;362(15): COMMIT (Methotrexate+ Infliximab (IFX) or IFX Feagan et al. Gastroenterology Mar;146(3):

4 COMMIT: IFX-Trough and IFX Antibody Levels n=126 patients, 63 IFX+MTX, 63 IFX Detectable p-value IFX Trough- p-value Antibody + p-value IFX level mg/ml IFX+MTX 52% 6.4 4% 0.84 <0.08 IFX 44% % <0.01 Feagan et al. Gastroenterology Mar;146(3): Differences SONIC and COMMIT Disease duration SONIC vs COMMIT (2.2 years vs 9 years). Immunosuppression SONIC no previous immunosuppression vs COMMIT 25% previous exposure and failure of azathioprine Inclusion criterion SONIC: CDAI > 220 and need for steroids, COMMIT patient in need for steroids (15-40mg) in the previous 4 weeks SONIC >70% prednisone naive at inclusion vs. COMMIT mean dose of prednisone 22 mg Trial Design SONIC: Dual therapy (IFX + AZA) vs COMMIT initial Steroid taper which might have masked the effects of MTX 4

5 Comparative Effectiveness of Anti-TNF in Crohn s disease Anti-TNF Timeline in Crohn s disease Infliximab Adalimumab Certolizumab FDA approval for Crohn s disease

6 Anti-TNF Timeline in Crohn s disease Infliximab Adalimumab Certolizumab FDA approval for Crohn s disease Anti-TNF Agents: Induction and Maintenance of Remission in Crohn s Disease Network Meta-analysis Overall Anti-TNF for Induction and Maintenance vs. Placebo Induction Remission RR: 1.66, 95% CI: ; Maintenance of Remission RR: 1.78, 95% CI: Induction therapy Comparison Infliximab (IFX) non-significant superiority to adalimumab (ADA) and certolizumab (CTZ) ADA superior to CTZ (RR: 2.93 for ADA vs. CZP, 95% CI: ) Maintenance Therapy Comparison Non-significant trends ADA>IFX>CTZ Stidham et al. Aliment Pharmacol Ther Jun;39(12):

7 Comparative Effectiveness Trials of Anti-TNF Agents in Crohn s Disease Total number of subjects required for comparative efficacy RCTs between anti-tnf agents for Induction / Maintenance of remission Infliximab Certolizumab Adalimumab Infliximab / / 3076 Certolizumab 3272 / / 286 Adalimumab 4780 / / Stidham et al. Aliment Pharmacol Ther Jun;39(12): Comparative Effectiveness Trials of Anti-TNF Agents in Crohn s Disease Total number of subjects required for comparative efficacy RCTs between anti-tnf agents for Induction / Maintenance of remission Infliximab Certolizumab Adalimumab Infliximab / / 3076 Certolizumab 3272 / / 286 Adalimumab 4780 / / Stidham et al. Aliment Pharmacol Ther Jun;39(12):

8 Recapturing Response with a 2 nd Anti-TNF in Crohn s disease Adalimumab Efficacy after Loss of Response/Intolerance to Infliximab (GAIN) 325 patients loss of response/intolerance IFX ADA week 0 (160 mg) + week 2 (80 mg) Placebo week 0 and 2 Outcome: Induction of remission Week 4 Remissio on (% patients) p<0.001 Sandborn et al. Ann Intern Med Jun 19;146(12):

9 Subgroup Analysis Adalimumab Efficacy after Loss of Response/Intolerance to Infliximab (GAIN) Variable Remission at week 4 Placebo Adalimumab Previous loss of response to IFX 8% 20% Previous intolerance to IFX 5% 22% Not receiving steroids at baseline 10% 15% Receiving steroids at baseline 4% 33% Negative IFX antibodies 8% 22% Indeterminate IFX antibodies 25% 17% Positive IFX antibodies 3% 22% Sandborn et al. Ann Intern Med Jun 19;146(12): Certolizumab Efficacy after Loss of Response/Intolerance to Infliximab (WELCOME) 539 patients loss of response IFX CTZ week 0,2 and 4 Week 4: RSP: 43.3% REM: 25.4% Week 6: RSP: 62.0% REM: 39.3% Response week 6 CTZ q 2 weeks CTZ q 4 weeks Week 26: REM CTZ q 2 weeks: 30.4% REM CTZ q 4 weeks: 29.2% Sandborn et al. Clin Gastroenterol Hepatol Aug;8(8):

10 Anti-Integrin Therapy in Crohn s disease Vedolizumab Therapy Blocking Cell Adhesion in the Gut 10

11 Vedolizumab (VDZ) in Crohn s Disease Short and Long-Term Efficacy (GEMINI 2) Induction of Remission Maintenance of Remission Week 6 Week 52 p<0.02 p<0.2 p<0.001 p<0.004 p<0.02 p<0.04 Sandborn et al. N Engl J Med Aug 22;369(8): Vedolizumab Efficacy After Previous anti-tnf Antagonist Failure in Crohn s Disease (GEMINI 3) Remission Week 6 Remission Week 10 Approx. 5% higher efficacy at week 10 with concomitant steroids. No clinical effects for concomitant immunosuppression week 6 and week 10. Sands et al. Gastroenterology Sep;147(3):

12 Summary Biologics in Crohn s Disease (CD) Overall there seem to be no significant differences between the different anti-tnf s in CD Combination therapy using infliximab and azathioprine/6-mp is superior to infliximab mono-therapy Adding Methotrexate to infliximab increases trough level and decreases antibody formation, but no effect on 1 year clinical outcome No prospective data for combination therapy adalimumab or certolizumab + azathioprine/6-mp or MTX in IBD Vedolizumab is effective in CD, but has a delayed onset of clinical efficacy, so far no data of inferiority i it of mono-therapy vs combination therapy Role for steroids with vedolizumab for induction of remission Algorithm for Induction and Maintenance of Remission in Crohn s Disease Flare with severe activity Flare with mild to moderate 1. Prednisone Relapse inflammatory activity 1. Budesonide (Entocort) Predictors of severe disease (perianal disease, young age, penetrating disease, isolated upper GI- disease) 2. (5-ASA) (?) or second flare in 12 months. Consider surgery no remission Azathioprine, 6-MP + anti-tnf agent (IFX) MTX + anti-tnf (IFX)? anti-tnf (ADA, CTZ) alone Vedolizumab (?) No remission or loss of response Induction regimen Induction and Maintenance regimen Switch anti-tnf agent or Vedolizumab 12

13 Anti-TNF in Ulcerative Colitis Therapeutic Success anti-tnf Therapy in UC Trial ACT-1 (IFX) ACT-2 (IFX) Ultra-1 (ADA) Ultra-2 (ADA) Ultra-2 anti- TNF naïve Pursuit (GOL) Clinical Remission Week 8 Delta Clinical Remission Week 52 or 54 Placebo anti-tnf Placebo anti-tnf Delta 15.0% 39.0% 24.0% 17.0% 35.0% 18% 6.0% 34.6% 28.6% % 18.5% 9.3% % 16.5% 7.2% 8.5% 17.3% 8.8% 11.0% 21.3% 10.3% 11.4% 22.0% 10.6% 6.3% * 18.7% * 12.4% 15.4% ** 28.6% ** 13.2% * Week 6 **Week 30 and 54 Rutgeerts et al. 2005, Reinisch et al. 2011, Sandborn et al. 2012; Sandborn et al

14 Infliximab Concentration and Clinical Outcome ACT1 and ACT2 Study Infliximab 5 mg/kg bodyweight week 0,2,6, IFX level week 8 Week 8 p=0.05 Week 30 p= Week 54 p= <21.3 >47.9 < >8.1 <33.0 <47.9 <6.8 <1.4 >6.8 <3.6 <8.1 <2.4 Reinisch W, et al. Presented at DDW; May 20, Abstract 566. *Data presented for the 5 mg/kg groups in ACT 1 & ACT 2 Factors Influencing the Pharmacokinetics of Anti-TNF Agents Presence of antibodies to drug increases clearance Lack of concomitant immunosuppression favors antibody formation High BMI increases clearance Probably only relevant for fixed dosed sc anti-tnf TNF levels High baseline TNF may increase clearance Albumin Low albumin predictor of failure Fecal Excretion of IFX High fecal secretion may be a predictor of failure Ordas et al. 2012; Brandse et al. DDW

15 Infliximab, Azathioprine or Combination UC SUCCESS Trial: Week 16 Results Patients naïve to anti-tnf and AZA or >3 months stop of AZA before trial Patients (%) p<0.02 p<0.03 p<0.02 p<0.001 p<0.001 p<0.03 Remission: Steroid-free + Mayo <2, Mucosal Healing: endoscopy 0 or 1 Panaccione et al Gastroenterology Feb;146(2): Anti-TNF Agents: Induction and Maintenance of Remission in Ulcerative Colitis Network Meta-analysis Overall Anti-TNF for Induction and Maintenance vs. Placebo Induction Remission RR 2.45, 95% CI: Maintenance of Remission RR: 2.00, 95% CI: Induction therapy Comparison Infliximab (IFX) with non-significant trends for superiority over golimumab (GOL) and adalimumab (ADA) Maintenance Therapy Comparison Non-significant trends IFX >ADA/GOL Stidham et al. Aliment Pharmacol Ther Apr;39(7):

16 Comparative Effectiveness Trails of Anti-TNF Agents in Ulcerative Colitis Total number of subjects required for comparative efficacy RCTs between anti-tnf agents for Induction / Maintenance of remission Infliximab Golimumab Adalimumab Infliximab / / 204 Golimumab 214 / / 420 Adalimumab 174 / / Stidham et al. Aliment Pharmacol Ther Apr;39(7): Comparative Effectiveness Trails of Anti-TNF Agents in Ulcerative Colitis Total number of subjects required for comparative efficacy RCTs between anti-tnf agents for Induction / Maintenance of remission Infliximab Golimumab Adalimumab Infliximab / / 204 Golimumab 214 / / 420 Adalimumab 174 / / PRACTICAL SIZE; SHOULD BE PERFORMED Stidham et al. Aliment Pharmacol Ther Apr;39(7):

17 Anti-Integrin in Ulcerative Colitis Vedolizumab (VDZ)in UC Clinical Response and Remission Week 6 Depending on Prior anti-tnf Exposure (GEMINI 1) n=145 n=206 Delta: 18.4% Delta: 6.6% Delta: 26.8% Delta: 16.5% Patients (%) Feagan et al N Engl J Med Aug 22;369(8):

18 Vedolizumab (VDZ) in UC Clinical Remission, Corticosteroidfree Remission and Mucosal Healing Week 52 (GEMINI 1) 895 patient included -373 patients responded at week 6 (42%) and were randomized Patients (%) p< p< p< p< p< p< Feagan et al N Engl J Med Aug 22;369(8): Therapeutic Pyramid in Ulcerative Colitis Infliximab, Adalimumab, Golimumab, Vedolizumab Cyclosporine (severe inpatient UC as bridge to other maintenance therapy) Azathioprine, 6-MP Vedolizumab (?) Steroids, Budesonide (Uceris) 5-ASA s 18

19 Severe Ulcerative Colitis Accelerated Infliximab Regimen for Severe Acute UC Retrospective analysis of 50 patients (35 standard and 15 accelerated protocol) Standard regimen of 5 mg/kg at 0,2,6 weeks compared to accelerated (5 mg/kg for 3 doses over a median of 24 days) p=0.039 Gibson DJ

20 Accelerated Infliximab Regimen for Severe Acute UC Changes in CRP Proportion colectomy-free Gibson DJ 2015 Algorithm for Severe Ulcerative Colitis Long MD

21 Algorithm for Severe Ulcerative Colitis Factors to consider that may influence the decision for accelerated infliximab dosing: Clinical severity CRP Albumin Long MD 2009 Summary Biologics in Ulcerative Colitis (UC) Infliximab with highest remission/response rates of the anti-tnfs Infliximab + azathioprine/6-mp is superior to infliximab monotherapy, but there are no data for adalimumab or golimumab combination therapy Trough levels play a role in the efficacy of anti-tnf agents in UC Vedolizumab is similarly effective when compared to anti-tnf agents, but may have a more favorable side effect profile? should vedolizumab be combined with azathioprine/6-mp or MTX to warrant long term efficacy In severe UC, accelerated dosing algorithms may improve shortterm colectomy rates, but prospective RCT s are needed 21

22 Acknowledgements Hans H. Herfarth MD, PhD 22

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and

More information

Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC

Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe

More information

Severe IBD: What to Do When Anti- TNFs Don t Work?

Severe IBD: What to Do When Anti- TNFs Don t Work? Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and

More information

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University

More information

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic

More information

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review

More information

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained

More information

Mono or Combination Therapy with. Individualized Approach

Mono or Combination Therapy with. Individualized Approach Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago

More information

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:

More information

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and

More information

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence

More information

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Immunogenicity of Biologic Agents and How to Prevent Sensitization

Immunogenicity of Biologic Agents and How to Prevent Sensitization Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning

More information

Indications for use of Infliximab

Indications for use of Infliximab Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of

More information

Positioning New Therapies

Positioning New Therapies Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Recent Advances in the Management of Refractory IBD

Recent Advances in the Management of Refractory IBD Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline

More information

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

CCFA. Crohns Disease vs UC: What is the best treatment for me? November CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York

More information

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features

More information

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical

More information

Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD

Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)

More information

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment

More information

How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009

How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009 How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

Common Questions in Crohn s Disease Therapy. Case

Common Questions in Crohn s Disease Therapy. Case Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound

More information

Positioning Biologics in Ulcerative Colitis

Positioning Biologics in Ulcerative Colitis Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies

More information

Personalized Medicine in IBD

Personalized Medicine in IBD Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016

More information

WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?

WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University

More information

Selection and use of the non-anti- TNF biological therapies: Who? When? How?

Selection and use of the non-anti- TNF biological therapies: Who? When? How? Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine

More information

The Refractory Crohn s Disease

The Refractory Crohn s Disease The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition

More information

Personalized Medicine in IBD: Where Are We in 2013

Personalized Medicine in IBD: Where Are We in 2013 Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized

More information

Endpoints for Stopping Treatment in UC

Endpoints for Stopping Treatment in UC Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

Il ruolo degli anticorpi anti farmaco nella pratica clinica

Il ruolo degli anticorpi anti farmaco nella pratica clinica Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring

More information

OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG

OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG 1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing

More information

Join the conversation at #GIFORUMCCFA

Join the conversation at #GIFORUMCCFA 1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the

More information

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &

More information

Mucosal healing: does it really matter?

Mucosal healing: does it really matter? Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does

More information

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10 Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University

More information

IBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh

IBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement

More information

Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA

Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications

More information

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4

More information

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD 5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED

More information

Anti tumor necrosis factor (TNF) agents have

Anti tumor necrosis factor (TNF) agents have Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical

More information

How to use infliximab?

How to use infliximab? How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!

More information

CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM

CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission

More information

2nd Nottingham IBD Masterclass, 2017

2nd Nottingham IBD Masterclass, 2017 2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory

More information

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:

More information

Management of Moderate to Severe Ulcerative Colitis

Management of Moderate to Severe Ulcerative Colitis Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann

More information

Ulcerative colitis (UC) is a chronic inflammatory

Ulcerative colitis (UC) is a chronic inflammatory Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance

More information

Medical Management of Inflammatory Bowel Disease

Medical Management of Inflammatory Bowel Disease Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,

More information

Drug Level Monitoring in IBD. Objectives

Drug Level Monitoring in IBD. Objectives Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug

More information

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard

More information

Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014

Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research

More information

Management of Refractory Crohn s Disease

Management of Refractory Crohn s Disease Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant

More information

Progress in Inflammatory Bowel Disease

Progress in Inflammatory Bowel Disease Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,

More information

Optimizing the treatment of IBD through use of therapeutic drug monitoring

Optimizing the treatment of IBD through use of therapeutic drug monitoring Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of

More information

Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.

Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,

More information

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker

More information

Optimal Use of Immunomodulators and Biologics

Optimal Use of Immunomodulators and Biologics 3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures

More information

New and Future Adhesion Molecule Based Therapies in IBD

New and Future Adhesion Molecule Based Therapies in IBD New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada

More information

IBD in teenagers Biological and Transition

IBD in teenagers Biological and Transition IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation

More information

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.

More information

Available Data on Pediatric Exposure Response a Clinician s Perspective

Available Data on Pediatric Exposure Response a Clinician s Perspective Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein

More information

New Perspectives on the Diagnosis and Management of IBD. Disclosures

New Perspectives on the Diagnosis and Management of IBD. Disclosures New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine

More information

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:

More information

Withdrawal of drug therapy in patients with quiescent Crohn s disease

Withdrawal of drug therapy in patients with quiescent Crohn s disease Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy

More information

Ali Keshavarzian MD Rush University Medical Center

Ali Keshavarzian MD Rush University Medical Center Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting

More information

Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner

More information

Selby Inflamm Bowel Dis. 2008:14:

Selby Inflamm Bowel Dis. 2008:14: Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory

More information

Latest Meds Approved for IBD: What are they and how do they work?

Latest Meds Approved for IBD: What are they and how do they work? Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA

More information

Therapy for Inflammatory Bowel Disease

Therapy for Inflammatory Bowel Disease Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current

More information

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,

More information

Crohn s

Crohn s Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures

More information

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Achieving Success in Ulcerative Colitis: the Role of Infliximab Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis

More information

Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico

Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis

Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Aránzazu Jáuregui Amézaga, Elena Ricart, Julián Panés Department of Gastroenterology, Hospital Clínic de Barcelona,

More information

Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF

Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine

More information

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice Journal of Crohn's and Colitis, 216, 26 3 doi:1.193/ecco-jcc/jjv169 Advance Access publication September 21, 215 Original Article Original Article Efficacy and Safety of Adalimumab in Ulcerative Colitis

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

ORIGINAL ARTICLE. Abstract. Introduction

ORIGINAL ARTICLE. Abstract. Introduction ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment

Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis

More information

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that

More information

Current and Emerging Biologics for Ulcerative Colitis

Current and Emerging Biologics for Ulcerative Colitis Gut and Liver, Vol. 9, No. 1, January 2015, pp. 18-27 Review Current and Emerging Biologics for Ulcerative Colitis Sung Chul Park* and Yoon Tae Jeen *Division of Gastroenterology and Hepatology, Department

More information

New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy

New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*

More information

Highlights of DDW 2015: Crohn s disease

Highlights of DDW 2015: Crohn s disease Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum

More information

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract

More information

The Best of IBD at UEGW (Crohn s)

The Best of IBD at UEGW (Crohn s) The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best

More information

CAG Symposium: Management of IBD in 2018

CAG Symposium: Management of IBD in 2018 CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles

More information

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification

More information